GW7647, >=98% (HPLC)

Not available outside of the UK & Ireland.

Application

GW7647 has been used as a peroxisome proliferator-activated receptor α (PPAR α) ligand: in defatting medium to treat primary human hepatocytes to test its effect on the glycolytic function in cardiomyocytes to test its effect on infant mouse heart in breast cancer MDA-MB-231 cells to activate PPARs

Biochem/physiol Actions

Potent human PPARα agonist. Use to study the biology of PPARα receptor in human cells.

GW7647 reduces serum triglyceride levels and enhances hepatic expression of genes associated with β-oxidation. Usage of GW7647 along with metformin in conditions of liver steatosis or injury improves the enzymatic levels of aspartate transaminase (AST) and alanine transaminase (ALT) in serum.

Features and Benefits

This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Legal Information

Sold for research purposes only under agreement from GlaxoSmithKline

Packaging

5, 25 mg in glass bottle